Mental health AI
Wysa
Wysa is a CBT-based mental health chatbot from Touchkin eServices with a free consumer app and large institutional deployments through employers, insurers, and NHS Talking Therapies, plus a 2025 merger with April Health that added human collaborative care. It holds a 2022 FDA Breakthrough Device designation for chronic pain with depression and anxiety, claims 36+ peer-reviewed publications, and earned praise from Mozilla for nickname-only privacy design. The CAIHL question is channel-dependent: the same chatbot reads as patient-directed self-help in the consumer app and as an institutional front door in employer and NHS deployments, where safety and usage signals can flow to the institution.
Public-source research has been drafted; final human publication review and change-log detail are still required.
Summary judgment · 55% toward patient-directed
Mixed, channel-dependent
Direct consumer use is anonymous-by-design and patient-chosen, but most deployment runs through employers, insurers, and the NHS, where institutions configure the service, receive usage and safety reporting, and position Wysa as a triage and waitlist layer.
Patient agency
How this tool changes agency
CBT exercises, a clinician-written care library, safety planning, SOS helpline signposting with follow-up, and pathways into human coaching or therapy are directly action-oriented, with peer-reviewed evidence of symptom improvement in several populations.
Anyone can download and use the core app free with only a nickname, but in employer, insurer, and NHS deployments Wysa is the offered digital front door for triage and waitlist support, and declining it can mean waiting for or finding human care another way.
Patient-facing signals
Who does this AI serve?
The app serves individual users with anonymous access and self-help tools, but revenue comes from employers, insurers, and health systems, and institutional deployments share aggregate usage data and, where configured, safety escalations with the purchasing institution.
Can patients tell AI is involved?
Wysa is openly presented as an AI chatbot, and the privacy policy states plainly that users are interacting with AI software and not a person, with human coach and clinician tiers labeled separately.
Can patients meaningfully choose?
Anyone can download and use the core app free with only a nickname, but in employer, insurer, and NHS deployments Wysa is the offered digital front door for triage and waitlist support, and declining it can mean waiting for or finding human care another way.
Can patients correct or challenge what the AI produces?
The policy gives correction, deletion, objection, and reset-my-data rights, and says conversations change when users say the AI is not helping, but there is no disclosed workflow for challenging an AI-supported triage outcome or institutional report in NHS or employer deployments.
Does it help patients understand or act?
CBT exercises, a clinician-written care library, safety planning, SOS helpline signposting with follow-up, and pathways into human coaching or therapy are directly action-oriented, with peer-reviewed evidence of symptom improvement in several populations.
Text findings
Who is left out or burdened?
Language, channel, and crisis-fit limits
The service is native English with select services in Spanish, French, German, Brazilian Portuguese, and some Indian languages; smartphone access is required; institutional access ties support to employment, coverage, or NHS referral; teen use depends on institutional approval; a 2018 BBC-reported test found earlier versions mishandled child abuse disclosures, which the company said it fixed.
What happens to patient data?
Strong public detail, with institutional-sharing caveat
Nickname-only consumer use, identifier scrubbing, zero data retention with the third-party LLM provider, no training of the external LLM on conversations, no sale of data, reset-my-data deletion, 10-year default retention, and ISO 27001/27701 certification are disclosed, but institutional deployments may share usage and safety data with the institution, and emergency detection may be reported to it.
Are the clinical boundaries clear?
Clear in wording
Materials state the AI supports but does not replace professional care, SOS pathways detect crisis language and signpost helplines, clinical safety follows DCB 0129, and the FDA Breakthrough Device designation from 2022 is a development-stage status, not marketing authorization; no FDA clearance was found in this review.
Who defined what good looks like?
Vendor-led with real academic partnerships
Wysa claims 36+ peer-reviewed publications with university partners and independent trials including an NHS clinical investigation, which is stronger than most consumer mental health apps, but most studies involve company participation and outcome definitions, and employer dashboards define value in workforce terms.
Review method
Public-source review of the official website, clinical-evidence page, global privacy policy, FDA Breakthrough Device press release, peer-reviewed study records, NHS deployment pages, Mozilla privacy review, and merger press coverage; no app walkthrough, vendor interview, or independent model evaluation.
Draft profile · Medium draft, official sources plus peer-reviewed studies and credible press